How many syringe units is a PT-141 dose?

It depends entirely on your water volume, which is why a static chart cannot answer it. Enter your vial size and water volume in the calculator and it returns the unit mark. The reconstitution chart below tabulates the common combinations.

Why is the dose the same at every experience level?

Because the engine dose table carries one figure for it across the levels, which is what you would expect from a compound with an approved human dose rather than a community-titrated range. The table shows that explicitly rather than manufacturing a ramp so the columns look busier.

How often can PT-141 be dosed?

The frequency string on the dose row states the limits verbatim: on demand, at least forty-five minutes before activity, no more than one dose in twenty-four hours, and no more than eight doses a month. Those numbers come from the approved label rather than from community practice, and the supplies table declines to compute a weekly count for exactly that reason: on-demand dosing has no fixed number of administrations per week, and inventing one would be worse than leaving the cell blank.

Why do I see a lower maximum quoted elsewhere?

Because two Klarovel data sources carry different ceilings for it and the page prints both. The engine dose table holds the approved figure; the older research row holds a lower conservative one. The engine dose table is the one that binds in production, because the dose guard reads its ceilings from there and falls back to the research row only where no dose row exists. The page names which figure binds rather than quietly publishing the lower one.

Bremelanotide is, for one indication and one population: premenopausal women with acquired, generalised hypoactive sexual desire disorder. The label is explicit that it is not indicated for postmenopausal women, not indicated for men, and not indicated to enhance sexual performance. Use outside that is use outside the approval, which is a fact about the regulatory status rather than a judgment about the compound.

Is PT-141 banned in drug-tested sport?

Bremelanotide does not appear on the World Anti-Doping Agency prohibited list, including its alphabetical index. That is unusual among the compounds with calculator pages here: growth hormone releasing hormone analogues, growth hormone secretagogues and growth hormone fragments are all listed under section S2 and prohibited at all times. If you compete under anti-doping rules, check the current list yourself rather than trusting any third party, this page included.

Does body weight change the PT-141 dose?

No. The engine catalog does not flag it weight sensitive and the dose calculator applies no generic weight scaling, so the tool leaves the target alone. A fixed approved dose is precisely the case where inventing a per-kilogram rule would be wrong.

When is PT-141 not appropriate?

The conditions table on this page lists every health condition the engine's contraindication matrix associates with this compound, with the engine's own stated reason and the severity. A public page cannot know your health data, so it names what would change the answer instead of guessing.

Where do the numbers on this page come from?

The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this peptide?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

PT-141 dosage calculator

PT-141 is bremelanotide, and unlike most compounds with a calculator page it has an approved human dose behind it. That makes the dose figure settled and the water volume the only thing left to decide.

Below the calculator: a reconstitution chart, the dose figure at every experience level, the on-demand dosing limits, the health conditions that change the answer, and the references. Every dose figure is read from the Klarovel engine's dose table, never typed into the page.

How many milligrams are in your PT-141 (Bremelanotide) vial?

How much bacteriostatic water are you adding?

Syringe size

Experience with injectable peptides

Selects the dose row the engine would use, which changes the target, the upper bound and the ceiling together.

Body weight

The engine catalog does not flag PT-141 (Bremelanotide) weight sensitive, and the dose calculator applies no generic weight scaling, so this does not change the target. Inventing a per-kilogram rule would be worse than leaving it alone.

Age 65 or over

Standard dose at the beginner level

35.0 units

1.75 mg

Concentration: 5 mg/ml
Injection volume: 0.35 ml
Doses per vial: 5

Frequency: as needed, at least 45 minutes before sexual activity; max 1 dose per 24 hours, max 8 doses per month. Timing: On demand. Route: subcutaneous.

Phase by phase, at your mix

The three phases in the order the engine escalates a dose, with the unit mark for each at 10 mg in 2 ml. Change the experience level, weight or age above and the whole table recomputes.

Dose and syringe units per titration phase
Phase	Dose	Draw	Doses per vial
Phase 1, opening dose	1.75 mg	35.0 units	5
Phase 2, standard dose	1.75 mg	35.0 units	5
Phase 3, upper dose	1.75 mg	35.0 units	5
Ceiling, not exceeded	1.75 mg	35.0 units	5

Doses read from the beginner row of dose_protocols, the engine's dose table. Unit marks are arithmetic over your vial size and water volume.

PT-141 (Bremelanotide) dose envelope by experience level

Every level side by side, unmodified. This is the raw dose table, so the shape of the ramp is visible instead of collapsed into a single recommended number.

Dose envelope per experience level
Experience	Opening	Standard	Upper	Ceiling	Frequency
Never used peptides	1.75 mg	1.75 mg	1.75 mg	1.75 mg	as needed, at least 45 minutes before sexual activity; max 1 dose per 24 hours, max 8 doses per month
Researched, not used	1.75 mg	1.75 mg	1.75 mg	1.75 mg	as needed, at least 45 minutes before sexual activity; max 1 dose per 24 hours, max 8 doses per month
Beginner	1.75 mg	1.75 mg	1.75 mg	1.75 mg	as needed, at least 45 minutes before sexual activity; max 1 dose per 24 hours, max 8 doses per month
Intermediate	1.75 mg	1.75 mg	1.75 mg	1.75 mg	as needed, at least 45 minutes before sexual activity; max 1 dose per 24 hours, max 8 doses per month
Experienced	1.75 mg	1.75 mg	1.75 mg	1.75 mg	as needed, at least 45 minutes before sexual activity; max 1 dose per 24 hours, max 8 doses per month

Every cell read verbatim from dose_protocols. Where a level repeats the same figure across columns, that is what the table holds: no ramp has been invented to fill the row.

PT-141 (Bremelanotide) reconstitution chart

Pre-calculated syringe units for every water volume against the dose figures this compound actually uses, at your selected vial size of 10 mg. A cell reading "n/a" means the draw exceeds a 100-unit syringe at that concentration.

Syringe units per water volume for each sourced dose figure
BAC water	Conc.	Opening1.75 mg	Standard1.75 mg	Upper1.75 mg	Ceiling1.75 mg
1 ml	10 mg/ml	17.5	17.5	17.5	17.5
1.5 ml	6.67 mg/ml	26.3	26.3	26.3	26.3
2 ml	5 mg/ml	35	35	35	35
2.5 ml	4 mg/ml	43.8	43.8	43.8	43.8
3 ml	3.33 mg/ml	52.5	52.5	52.5	52.5
4 ml	2.5 mg/ml	70	70	70	70
5 ml	2 mg/ml	87.5	87.5	87.5	87.5

Column doses are the beginner row's opening, standard, upper and ceiling figures from dose_protocols. Unit marks are arithmetic.

Supplies for one cycle

One on-cycle runs 52 weeks followed by 0 weeks off, from the engine catalog. Multiplied out at the standard dose and your mix, that is what the cycle costs in consumables.

Bacteriostatic water bottle size

Supplies are not computed for this combination, because the frequency string on this dose row does not map to a fixed number of administrations per week and a supply figure is not worth guessing at.

Cycle length, loading phase and taper from PEPTIDE_CATALOG. Administrations per week derived from the frequency string on the dose row. Counts are arithmetic.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

About PT-141 (Bremelanotide)

PT-141 is bremelanotide, a melanocortin receptor agonist and a cyclic analogue of the alpha-melanocyte-stimulating hormone family. Unlike most of the catalog it reached approval: the FDA approved it on 21 June 2019 under NDA 210557, marketed as Vyleesi, for premenopausal women with acquired, generalised hypoactive sexual desire disorder. The two RECONNECT phase 3 trials behind that decision were published in Obstetrics and Gynecology in 2019, and a safety analysis across the whole development programme followed in 2022.

Approval is why the dose figure on this page does not move with experience level. The engine dose table carries the labelled figure at every level rather than inventing a ramp to fill the columns, and the frequency string carries the label's own two limits verbatim: no more than one dose in twenty-four hours, and more than eight doses a month is not recommended. Those limits are part of the dose, not advice attached to it.

One honest caveat about what this calculator is for. The approved product is a single-use autoinjector holding a fixed volume, so nobody reconstitutes it. A vial of lyophilised powder is a different presentation, and reconstitution arithmetic is what a reader with a vial actually needs. The dose target the calculator aims at is the sourced one either way, and the reference list below is the clinical literature on the compound rather than a set of dose citations.

Administration and cycling

Administration and cycling reference
Route	subcutaneous
Timing	On demand
Catalog frequency	As needed, max 8x/month
Cycle	52 weeks on, 0 weeks off
Taper before the off period	Not specified
Loading phase	None
Weight sensitive	No

Catalog note: Inject subcutaneously at least 45 minutes before activity. Maximum one dose per 24 hours and no more than 8 doses per month. May cause nausea on first use.

Every row above is read from PEPTIDE_CATALOG, the engine catalog, and the note is quoted verbatim rather than paraphrased.

Two ceilings, and which one binds

Klarovel holds two upper bounds for PT-141 (Bremelanotide) in two different places, and they do not agree. The engine dose table puts the highest ceiling at 1.75 mg across the experience levels. The older research row carries 1 mg.

The engine dose table is the one that binds. The dose guard that caps generated protocols reads its ceilings from that table and falls back to the research row only where no dose row exists, because a guard that fights the engine trims legitimately curated doses and trains everyone to ignore its warnings.

Both figures are printed here rather than one, so a reader who finds the lower number elsewhere can see that both exist and which one the software actually uses.

When this would not be recommended for you

A public page cannot know your health data, so it cannot tell you whether a compound is appropriate. What it can do is list the conditions the engine's contraindication matrix associates with this compound, and what the engine does about each. In a generated protocol these resolve automatically and the reason is shown alongside the exclusion.

Health conditions and the engine's action
Condition	Engine action	Reason
Uncontrolled hypertension	Excluded	PT-141 may cause acute blood pressure elevation. Contraindicated with uncontrolled hypertension.
Heart condition	Caution	PT-141 may cause transient blood pressure elevation. Cardiological clearance recommended with known heart disease.
Mental health	Monitored	PT-141 may affect mood via the melanocortin system. Monitor mood changes with mental health conditions.

Conditions, severities and reasons read verbatim from CONTRAINDICATION_RULES, the engine's contraindication matrix. This is not the full set of things worth raising with a clinician; it is the set the engine acts on.

Questions

How many syringe units is a PT-141 dose?: It depends entirely on your water volume, which is why a static chart cannot answer it. Enter your vial size and water volume in the calculator and it returns the unit mark. The reconstitution chart below tabulates the common combinations.
Why is the dose the same at every experience level?: Because the engine dose table carries one figure for it across the levels, which is what you would expect from a compound with an approved human dose rather than a community-titrated range. The table shows that explicitly rather than manufacturing a ramp so the columns look busier.
How often can PT-141 be dosed?: The frequency string on the dose row states the limits verbatim: on demand, at least forty-five minutes before activity, no more than one dose in twenty-four hours, and no more than eight doses a month. Those numbers come from the approved label rather than from community practice, and the supplies table declines to compute a weekly count for exactly that reason: on-demand dosing has no fixed number of administrations per week, and inventing one would be worse than leaving the cell blank.
Why do I see a lower maximum quoted elsewhere?: Because two Klarovel data sources carry different ceilings for it and the page prints both. The engine dose table holds the approved figure; the older research row holds a lower conservative one. The engine dose table is the one that binds in production, because the dose guard reads its ceilings from there and falls back to the research row only where no dose row exists. The page names which figure binds rather than quietly publishing the lower one.
Is PT-141 approved?: Bremelanotide is, for one indication and one population: premenopausal women with acquired, generalised hypoactive sexual desire disorder. The label is explicit that it is not indicated for postmenopausal women, not indicated for men, and not indicated to enhance sexual performance. Use outside that is use outside the approval, which is a fact about the regulatory status rather than a judgment about the compound.
Is PT-141 banned in drug-tested sport?: Bremelanotide does not appear on the World Anti-Doping Agency prohibited list, including its alphabetical index. That is unusual among the compounds with calculator pages here: growth hormone releasing hormone analogues, growth hormone secretagogues and growth hormone fragments are all listed under section S2 and prohibited at all times. If you compete under anti-doping rules, check the current list yourself rather than trusting any third party, this page included.
Does body weight change the PT-141 dose?: No. The engine catalog does not flag it weight sensitive and the dose calculator applies no generic weight scaling, so the tool leaves the target alone. A fixed approved dose is precisely the case where inventing a per-kilogram rule would be wrong.
When is PT-141 not appropriate?: The conditions table on this page lists every health condition the engine's contraindication matrix associates with this compound, with the engine's own stated reason and the severity. A public page cannot know your health data, so it names what would change the answer instead of guessing.
Where do the numbers on this page come from?: The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this peptide?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other peptide calculators

References

These papers cover bremelanotide from mechanism through approval: the melanocortin pharmacology, the early arousal studies, the two RECONNECT phase 3 trials, the pooled safety analysis, and two published critiques of the phase 3 evidence. The critiques are included deliberately. A reference list that carries only the favourable half of a literature is a marketing document.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

12 references, every identifier resolved against NCBI on 2026-08-03. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query). Regenerated 2026-08-03 for cjc1295_no_dac, ipamorelin, pt141, retatrutide, aod9604 and sermorelin using the same esearch + esummary procedure; no record was added whose esummary payload lacked a title, journal or first author.

1.Dhillon S et al. Bremelanotide: First Approval. Drugs 2019. PMID 31429064
2.Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019. PMID 31599840 PMC6819021
3.Clayton AH et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt) 2022. PMID 35147466
4.Simon JA et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt) 2022. PMID 35230162
5.Pfaus JG et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr 2022. PMID 33455598
6.Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006. PMID 16839319
7.Mayer D et al. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother 2020. PMID 31893927
8.Spielmans GI et al. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res 2021. PMID 33678061
9.Mintzes B et al. Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug Ther Bull 2021. PMID 34642243
10.Cipriani S et al. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opin Pharmacother 2023. PMID 36242769
11.Spana C et al. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab 2022. PMID 35170192 PMC9314948
12.Sweeney P et al. Targeting the central melanocortin system for the treatment of metabolic disorders. Nat Rev Endocrinol 2023. PMID 37365323

Beyond the arithmetic

Your health data, your protocol.

A calculator converts a dose into syringe units. The Klarovel engine decides the dose: it reads your health data, resolves contraindications, sets the envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.